Remus Pharmaceuticals Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Remus Pharmaceuticals Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Remus Pharmaceuticals shares trading at Rs.772 against a market capitalisation of Rs.904 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Remus Pharmaceuticals enters the Remus Pharmaceuticals Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Remus Pharmaceuticals are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Remus Pharmaceuticals Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Remus Pharmaceuticals Research at Univest

Remus Pharmaceuticals (NSE: REMUS) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings ahead of the Remus Pharmaceuticals Q1 Results FY27 season, forming the base against which the Remus Pharmaceuticals Q1 Results FY27 estimates in this article are built. This Remus Pharmaceuticals Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Remus Pharmaceuticals Q1 FY27 Estimates

Metric	Detail
CMP	Rs.772
Market Cap	Rs.904 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.780-880

Univest, a SEBI-Registered Investment Advisor, Tracks Remus Pharmaceuticals Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Remus Pharmaceuticals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Remus Pharmaceuticals share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Remus Pharmaceuticals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Remus Pharmaceuticals share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Remus Pharmaceuticals’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Remus Pharmaceuticals share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Remus Pharmaceuticals’s live price and Q1 FY27 result updates.

Key Risks to the Remus Pharmaceuticals Q1 Results FY27 Outlook

• Pricing pressure in key export markets, particularly the US generics segment.
• Regulatory or plant compliance issues affecting supply continuity.
• R&D and capacity expansion costs weighing on near-term profitability.

Recent Performance Context

Detailed recent-quarter financials for Remus Pharmaceuticals were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Remus Pharmaceuticals Q1 Results FY27

Remus Pharmaceuticals shares last traded at Rs.772. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Remus Pharmaceuticals Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Remus Pharmaceuticals Q1 Results FY27 trailing-growth framework points to a range of Rs.757-819 for Remus Pharmaceuticals, contingent on the Remus Pharmaceuticals Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Remus Pharmaceuticals Q1 Results FY27 view for Remus Pharmaceuticals works out to Rs.780-880, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Remus Pharmaceuticals Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Remus Pharmaceuticals Q1 Results FY27 analysis would put Remus Pharmaceuticals in a Rs.823-962 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Remus Pharmaceuticals Q1 Results FY27 Print

• Revenue and PAT versus the Remus Pharmaceuticals Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Remus Pharmaceuticals Q1 Results FY27 narrative.
• Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
• Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Remus Pharmaceuticals Q1 Results FY27

Remus Pharmaceuticals enters the Q1 FY27 results season trading at Rs.772, with the 12-month Uniresearch target range of Rs.780-880 reflecting a tracking stance. Investors tracking the Remus Pharmaceuticals Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Remus Pharmaceuticals Q1 Results FY27

When are Remus Pharmaceuticals Q1 FY27 results expected?

Ans. Remus Pharmaceuticals’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Remus Pharmaceuticals Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Remus Pharmaceuticals at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Remus Pharmaceuticals share price target?

Ans. The 12-month Uniresearch estimate for Remus Pharmaceuticals share price target is Rs.780-880, based on trailing growth and current valuation multiples.

Is Remus Pharmaceuticals a good buy before Q1 FY27 results?

Ans. Remus Pharmaceuticals is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Remus Pharmaceuticals’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Remus Pharmaceuticals share price live?

Ans. Remus Pharmaceuticals share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.